William Hartzel - 06 Feb 2026 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Signature
/s/ Richard S. Lindahl, Attorney-in-fact
Issuer symbol
EBS
Transactions as of
06 Feb 2026
Net transactions value
-$69,899
Form type
4
Filing time
10 Feb 2026, 19:06:54 UTC
Previous filing
13 Nov 2025
Next filing
05 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hartzel William SVP, Bioservices 300 PROFESSIONAL DRIVE, GAITHERSBURG /s/ Richard S. Lindahl, Attorney-in-fact 10 Feb 2026 0001989644

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EBS Common Stock Disposed to Issuer $63,019 -5,771 -5.6% $10.92 97,311 06 Feb 2026 Direct F1
transaction EBS Common Stock Tax liability $6,880 -630 -0.65% $10.92 96,681 06 Feb 2026 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 1,922 shares of common stock, which is less than the 7,693 shares previously reported on March 02, 2023 and June 09, 2023.
F2 Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units